Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET Â | Source: C4 Therapeutics, Inc. Cemsidomide in…
Virbac:: Paul Martingell’s compensation terms
The board of directors of Virbac specifies Paul Martingell's compensation terms as…
A Road Adventure Like No Other with DragOn Drive Club Rally
Tuesday 15 April, 2025 Date: June 13 - June 21, 2025 Location:…
Enfinity Global Sells Minority Stakes in 380 MW Energy Storage Projects in the US and Italy to Daiwa Energy & Infrastructure
MIAMI, June 4, 2025 /PRNewswire/ -- Enfinity Global Inc., a leading renewable…
